Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.62 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.61 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.59 |
| ▸ | CA12 | O43570 | 2/20 | 0.59 |
| ▸ | CA1 | P00915 | 2/20 | 0.59 |
| ▸ | CA2 | P00918 | 2/20 | 0.59 |
| ▸ | CA9 | Q16790 | 2/20 | 0.59 |
| ▸ | ACHE | P22303 | 1/20 | 0.59 |
| ▸ | CA4 | P22748 | 1/20 | 0.59 |
| ▸ | PKM | P14618 | 1/20 | 0.55 |
| ▸ | MEN1 | O00255 | 2/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.54 |
| ▸ | RAB9A | P51151 | 1/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.54 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8083585 | 0.90 | POLB (0.69) | POLBKDM4EALOX5CA12CA1 | |
| SCHEMBL13486978 | 0.88 | POLB (0.67) | POLBKDM4EALOX5CA12CA1 | |
| SCHEMBL28639253 | 0.87 | ALOX5 (0.62) | POLBKDM4EALOX5CA12CA1 | |
| SCHEMBL8090142 | 0.84 | ACHE (0.62) | ALOX5CA12CA1CA2CA9 | |
| SCHEMBL4234495 | 0.84 | RAB9A (0.66) | KDM4EALOX5CA12CA1CA2 | |
| SCHEMBL8091526 | 0.82 | MEN1 (0.58) | POLBKDM4EALOX5CA12CA1 | |
| SCHEMBL1569306 | 0.82 | ACHE (0.60) | POLBALOX5CA12CA1CA2 | |
| SCHEMBL2001911 | 0.81 | MEN1 (0.63) | POLBKDM4EALOX5CA12CA1 | |
| SCHEMBL6956819 | 0.81 | ALOX5 (0.62) | KDM4EALOX5CA12CA1CA2 | |
| SCHEMBL6207633 | 0.81 | ALOX5 (0.62) | POLBKDM4EALOX5CA12CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100004222-A1 | Amide Derivatives as Ion-Channel Ligands and Pharmaceutical Compositions and Methods of Using the Same | RENOVIS, INC. (US) | 2010-01-07 | — | — | US | disclosed |
| US-20100004222-A1 | Amide Derivatives as Ion-Channel Ligands and Pharmaceutical Compositions and Methods of Using the Same | RENOVIS, INC. (US) | 2010-01-07 | — | — | US | disclosed |
| US-20100004222-A1 | Amide Derivatives as Ion-Channel Ligands and Pharmaceutical Compositions and Methods of Using the Same | RENOVIS, INC. (US) | 2010-01-07 | — | — | US | disclosed |
| EP-1954132-A2 | AMIDE DERIVATIVES AS ION-CHANNEL LIGANDS AND PHARMACEUTICAL COMPOSITIONS AND METHODS OF USING THE SAME | Renovis, Inc. (US) | 2008-08-13 | — | — | EP | disclosed |
| WO-2007100758-A2 | AMIDE DERIVATIVES AS ION-CHANNEL LIGANDS AND PHARMACEUTICAL COMPOSITIONS AND METHODS OF USING THE SAME | RENOVIS, INC. (US) | 2007-09-07 | — | — | WO | disclosed |
| WO-2007100758-A2 | AMIDE DERIVATIVES AS ION-CHANNEL LIGANDS AND PHARMACEUTICAL COMPOSITIONS AND METHODS OF USING THE SAME | RENOVIS, INC. (US) | 2007-09-07 | — | — | WO | disclosed |
| US-4324719-A | YELLOW TO BLUE SHADES ON NYLON CARPET | EASTMAN KODAK COMPANY (US) | 1982-04-13 | — | — | US | disclosed |
| US-4039522-A | Phthalimidyl-azo-m-acylamido-n-substituted aniline compounds and polyester fibers dyed therewith | EASTMAN KODAK COMPANY (US) | 1977-08-02 | — | — | US | disclosed |
| US-4012372-A | MONOAZO DISPERSE DYES | EASTMAN KODAK COMPANY (US) | 1977-03-15 | — | — | US | disclosed |
| US-3980634-A | Phthalimidyl-azo aniline type compounds and polyester fibers dyed therewith | EASTMAN KODAK COMPANY (US) | 1976-09-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100004222-A1 | Amide Derivatives as Ion-Channel Ligands and Pharmaceutical Compositions and Methods of Using the Same | TRPV1, TRPA1, TRPV2 | POLB 4421/4885KDM4E 4075/4885ALOX5 293/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.